An advisory panel of the U.S. Food and Drug Administration (FDA) has voted unanimously that antibodies against nerve growth factor (NGF) should re-enter clinical trials for pain. The 21-person Arthritis…
Antibodies inhibiting nerve growth factor (NGF) are profoundly effective pain relievers in clinical trials, and, if approved, would become the first new class of analgesics for osteoarthritis, and possibly many…
In animal models, measuring responses to evoked pain is relatively straightforward, but it is a formidable challenge to figure out whether an animal is in pain, and whether an analgesic…
How does chronic pain start? Many researchers now believe the bulk of the blame falls on the brain. But how can we make the pain stop? When it comes to…
